| Literature DB >> 35031667 |
Nam Hoon Moon1, Min Uk Do2, Jung Shin Kim2, Jae Seung Seo2, Won Chul Shin3.
Abstract
This study aimed to evaluate the early results of primary total hip arthroplasty (THA) using dual mobility (DM) cups in patients at a risk of dislocation and compare them with that of fixed bearing (FB) THA. This retrospective study included patients who had undergone primary THA between January 2016 and December 2018 and were at a risk of dislocation. A propensity score-matched analysis was conducted for 63 THA procedures with vitamin-E infused highly cross-linked polyethylene (VEPE) DM bearing and 63 THA procedures performed with FB from the same manufacturer for a mean follow-up period of 3.1 and 3.5 years, respectively. The radiologic outcomes at the last follow-up and incidence of postoperative complications were evaluated and compared statistically between the two groups. The modified Harris hip score (mHHS) was used to assess patient-reported outcomes. Postoperative dislocation occurred in 4 cases (6.3%) in the FB group, but did not occur in the DM group (p = 0.042). There was no difference in the radiologic outcomes and postoperative complications between the two groups. The mHHS at the last follow-up showed satisfactory outcomes in both the groups (DM group, 90.5; FB group, 88.1), without a statistical difference between the groups. The early results of THA using VEPE DM bearing showed better outcomes than that of THA with FB for patients at a risk of dislocation. A longer follow-up period is recommended to assess the stability and overall outcomes.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35031667 PMCID: PMC8760308 DOI: 10.1038/s41598-022-04774-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study design flowchart.
Preoperative demographics in a matched group with at least 2 years average follow-up.
| Demographics | DM THA | FB THA | |
|---|---|---|---|
| Number | 63 | 63 | |
| Age, mean ± SD, years | 61.6 ± 15.0 | 60.5 ± 13.6 | 0.667 |
| Gender, F:M | 40:23 | 38:25 | 0.714 |
| BMI, mean ± SD, kg/m2 | 23.8 ± 4.1 | 24.5 ± 3.3 | 0.284 |
| BMD, mean ± SD, T-score | −1.8 ± 1.3 | −1.2 ± 1.3 | 0.019 |
| Follow-up, mean ± SD, years | 3.1 ± 0.7 | 3.5 ± 1.2 | 1.000 |
| Osteoarthritis | 28 | 37 | 0.109 |
| Osteonecrosis | 17 | 10 | 0.129 |
| Femoral neck fracture | 8 | 5 | 0.380 |
| Acetabular fracture | 1 | 2 | 0.559 |
| Internal fixation failure | 6 | 7 | 0.770 |
| Ankylosed hip | 3 | 2 | 0.648 |
| Deformed spine disease | 18 | 13 | 0.301 |
| Dysplastic hip | 17 | 21 | 0.437 |
| Legg-Calvé-Perthes | 3 | 2 | 0.648 |
| Neuromuscular disorder | 12 | 11 | 0.818 |
| Hip fracture | 7 | 7 | 1.000 |
| Previous femoral neck fracture | 7 | 7 | 1.000 |
| Previous intertrochanteric fracture | 9 | 7 | 0.593 |
| Previous acetabular fracture | 3 | 3 | 1.000 |
| Ankylosing spondylitis | 4 | 3 | 0.697 |
| Hypertension | 27 | 23 | 0.466 |
| Diabetes | 11 | 9 | 0.626 |
| Dyslipidemia | 15 | 3 | 0.002 |
| Cerebral infarction | 8 | 4 | 0.225 |
| Chronic kidney disease | 2 | 1 | 0.559 |
| Hepatitis | 2 | 2 | 1.000 |
| Cardiac disease | 7 | 2 | 0.084 |
| Pulmonary disease | 3 | 3 | 1.000 |
| Hypothyroidism | 1 | 3 | 0.310 |
| Other neuromuscular disorders | 6 | 4 | 0.510 |
| Rheumatoid arthritis | 3 | 6 | 0.299 |
| Ankylosing spondylitis | 4 | 3 | 0.697 |
| Organ cancer | 5 | 2 | 0.243 |
| Dementia | 1 | 1 | 1.000 |
| 1 | 17 | 23 | 0.251 |
| 2 | 40 | 33 | 0.207 |
| 3 | 6 | 7 | 0.770 |
BMD bone mineral density, BMI body mass index, DM dual mobility, F female, FB fixed bearing, M male, SD standard deviation, THA total hip arthroplasty.
Operative data in DM and FB THA cohort.
| Demographics | DM THA | FB THA | |
|---|---|---|---|
| Trilogy® | 0 | 23 | |
| G7® | 63 | 40 | |
| 2nd generation HXLPE (Longevity®) standard | 0 | 16 | |
| 2nd generation HXLPE (Longevity®) elevated | 0 | 7 | |
| 3rd generation HXLPE (E1®) | 63 | 40 | |
| Cup anteversion, mean ± SD, ° | 21.0 ± 4.5 | 23.0 ± 4.4 | 0.021 |
| Cup inclination, mean ± SD, ° | 40.2 ± 4.3 | 41.9 ± 4.3 | 0.056 |
| Cup size, mean ± SD, mm | 53.1 ± 3.7 | 51.8 ± 3.2 | 0.059 |
| Ceramic (Biolox delta, CeramTec) | 63 | 63 | |
| Size, mean ± SD, mm | 28 ± 0.0 | 33.0 ± 2.4 | 0.001 |
| 28 mm | 63 | 5 | |
| 32 mm | 0 | 38 | |
| 36 mm | 0 | 20 | |
| Neck length, mean ± SD, mm | −0.1 ± 2.6 | −0.4 ± 2.3 | 0.051 |
| Versys® Fiber Metal Taper | 7 | 20 | |
| Wager SL Revision® | 7 | 7 | |
| Microplasty® | 49 | 36 | |
| General | 61 | 61 | |
| Spinal | 2 | 2 | |
| Operating time, mean ± SD, minutes | 77.9 ± 24.2 | 83.7 ± 37.4 | 0.311 |
DM dual mobility, FB fixed bearing, HXLPE highly cross-linked polyethylene, SD standard deviation, THA total hip arthroplasty.
Postoperative outcomes in DM and FB THA cohort.
| Demographics | DM THA | FB THA | |
|---|---|---|---|
| Osteolysis (%) | 1 (1.6%) | 2 (3.2%) | 0.559 |
| Implant loosening (%) | 0 (0.0%) | 0 (0%) | 1.000 |
| Reoperation (%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Dislocation (%) | 0 (0.0%) | 4 (6.3%) | 0.042 |
| Intraprosthetic dissociation (%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Intraoperative periprosthetic fracture (%) | 3 (4.8%) | 0 (0.0%) | 0.079 |
| Venous thromboembolism (%) | 0 (0.0%) | 1 (1.6%) | 0.315 |
| Deep joint Infection (%) | 0 (0.0%) | 1 (1.6%) | 0.315 |
| Medical complication (%) | 5 (7.9%) | 5 (7.9%) | 1.000 |
| Pneumonia | 3 | 1 | 0.310 |
| Urinary tract infection | 1 | 1 | 1.000 |
| Enteritis with Ileus | 1 | 2 | 0.559 |
| Rheumatoid flare | 0 | 1 | 0.315 |
| mHHS at the last FU, mean ± SD (range) | 90.5 ± 9.8 (68–100) | 88.1 ± 9.5 (58–100) | 0.245 |
DM dual mobility, FB fixed bearing, FU follow-up, mHHS modified Harris hip score, THA total hip arthroplasty.